海角视频

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Manufacturing

Coronavirus vaccine maker AstraZeneca's 拢27.5bn Alexion deal cleared for go ahead

The deal was first announced in December 2020

AstraZeneca has a major base in Cheshire(Image: PA)

Coronavirus vaccine maker AstraZeneca's £27.5bn ($39bn) deal to buy an American drug company is set to be completed next week after being cleared by the 海角视频's competition watchdog.

The Competition and Markets Authority (CMA) said in May it was looking into whether AstraZeneca's acquisition of Alexion Pharmaceuticals could harm competition in the 海角视频.

AstraZeneca, which has a major base in Macclesfield, Cheshire, agreed to buy Alexion in Boston for £123 ($175) a share in December, marking the drug giant's biggest ever acquisition and a move to boost its expertise in immunology and rare diseases.

The cash-and-shares deal was approved by shareholders in May, before the CMA got involved.

It is a milestone for AstraZeneca - which has developed the Covid-19 jab together with Oxford University - and will diversify the group, adding to its fast-growing cancer treatment business.

AstraZeneca has said it hopes the deal will now be completed on July 21.

Marc Dunoyer, AstraZeneca's executive director and chief financial officer, said: "We are very pleased to have secured this critical final clearance from the 海角视频 Competition and Markets Authority for the acquisition of Alexion.